Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline PEP for STI Prevention in MSM
NCT03980223Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Nov 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxycycline in gonorrhea, Chlamydia trachomatis infection (CT) and syphilis (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Number of Quarterly Visits In Which an STI Was Detected at 1 year. Started Nov 2019; status: completed.
02
Drugs
doxycycline
03
Conditions
gonorrheaChlamydia trachomatis infection (CT)syphilis
Beyond the preview
Go deeper on NCT03980223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980223.